Aurinia Pharmaceuticals Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Aurinia Pharmaceuticals Inc. (AUPH), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are AUPH insiders buying or selling?
In the last 12 months, Aurinia Pharmaceuticals Inc. insiders reported 2 open-market purchases ($25.1M) and 2 sales ($546.4K) — net buying of $24.6M. Since January 2021, Trabud has recorded 80 Form 4 filings for AUPH: 20 buys ($63.2M) and 60 sells ($42.9M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $12.7M by TANG KEVIN (Director) on Mar 3, 2026. SEC ↗
- The most recent open-market purchase was reported on Jun 3, 2026 (4 months ago).
Key Statistics (January 2021 – Sep 11, 2026)
Total Form 4 filings
80
SEC EDGAR
Insider filers
20
Insider buys (20)
$63.2M
Insider sells (60)
$42.9M
Insider sentiment
Net buyingNet insider flow of $20.3M in net buying since January 2021, and $24.6M in net buying over the last 12 months.
Recent AUPH insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Stephen P. Robertson | Chief Legal Officer | Sale | 11.9K | $15.95 | $190.4K | SEC ↗ |
| Aug 26, 2026 | Stephen P. Robertson | Chief Legal Officer | Sale | 21.0K | $16.97 | $355.9K | SEC ↗ |
| Jun 3, 2026 | Kevin Tang | Chief Executive Officer | Purchase | 814.6K | $15.29 | $12.5M | SEC ↗ |
| Mar 3, 2026 | TANG KEVIN | Director | Purchase | 900.0K | $14.10 | $12.7M | SEC ↗ |
| Aug 5, 2025 | TANG KEVIN | Director | Purchase | 1.3M | $10.45 | $13.6M | SEC ↗ |
| Aug 5, 2025 | Greg Keenan | Chief Medical Officer | Sale | 20.0K | $10.50 | $210.0K | SEC ↗ |
| Mar 7, 2025 | Greg Keenan | Chief Medical Officer | Sale | 8.3K | $8.23 | $68.4K | SEC ↗ |
| Mar 5, 2025 | Peter Greenleaf | Chief Executive Officer | Sale | 360.5K | $7.96 | $2.9M | SEC ↗ |
| Mar 5, 2025 | Greg Keenan | Chief Medical Officer | Sale | 12.2K | $8.00 | $97.9K | SEC ↗ |
| Mar 5, 2025 | Joseph M Miller | Chief Financial Officer | Sale | 118.0K | $7.96 | $939.6K | SEC ↗ |
| Mar 5, 2025 | Stephen P. Robertson | EVP, General Counsel | Sale | 122.5K | $7.96 | $975.2K | SEC ↗ |
| Mar 5, 2025 | Matthew Maxwell Donley | Chief Operating Officer | Sale | 124.9K | $7.96 | $994.4K | SEC ↗ |
| Mar 4, 2025 | TANG KEVIN | Director | Purchase | 1.6M | $7.95 | $12.7M | SEC ↗ |
| Dec 9, 2024 | TANG KEVIN | Director | Purchase | 1.2M | $9.02 | $10.8M | SEC ↗ |
| Nov 13, 2024 | Jeffrey Allen Bailey | Director | Sale | 4.6K | $8.43 | $38.4K | SEC ↗ |
| Nov 13, 2024 | Karen L. Smith | Director | Sale | 5.2K | $8.43 | $44.2K | SEC ↗ |
| Aug 8, 2024 | Scott Michael Habig | Chief Commercial Officer | Sale | 18.2K | $5.31 | $96.9K | SEC ↗ |
| May 22, 2024 | David R.W. Jayne | Director | Sale | 4.9K | $5.74 | $28.4K | SEC ↗ |
| Mar 7, 2024 | Peter Greenleaf | Chief Executive Officer | Sale | 127.0K | $5.60 | $711.1K | SEC ↗ |
| Mar 7, 2024 | Joseph M Miller | Chief Financial Officer | Sale | 34.8K | $5.60 | $194.9K | SEC ↗ |
| Mar 7, 2024 | Matthew Maxwell Donley | EVP, Ops & Strategy | Sale | 40.7K | $5.51 | $224.1K | SEC ↗ |
| Mar 7, 2024 | Scott Michael Habig | Chief Commercial Officer | Sale | 17.8K | $5.60 | $99.6K | SEC ↗ |
| Mar 7, 2024 | Stephen P. Robertson | EVP, General Counsel | Sale | 57.7K | $5.60 | $323.4K | SEC ↗ |
| Feb 29, 2024 | Volker Knappertz | EVP, Research and Development | Sale | 4.9K | $6.10 | $30.1K | SEC ↗ |
| Feb 22, 2024 | Volker Knappertz | EVP, Research and Development | Sale | 25.1K | $5.48 | $137.8K | SEC ↗ |
Showing the 25 most recent of 80 Form 4 filings for Aurinia Pharmaceuticals Inc..
Most active AUPH insiders
- Michael Robert Martin12 filings
- Neil Solomons7 filings
- Stephen P. Robertson7 filings
- Joseph M Miller6 filings
- Peter Greenleaf6 filings
Ask anything about AUPH insider activity
Use Trabud's AI agent to query Aurinia Pharmaceuticals Inc.'s Form 4 history in plain English — "Show me AUPH CEO purchases this year" or compare it against any other ticker.
Open the AI agentAUPH insider trading FAQ
Are Aurinia Pharmaceuticals Inc. insiders buying or selling?
In the last 12 months, Aurinia Pharmaceuticals Inc. insiders reported 2 open-market purchases ($25.1M) and 2 sales ($546.4K) — net buying of $24.6M. Since January 2021, Trabud has recorded 80 Form 4 filings for AUPH: 20 buys ($63.2M) and 60 sells ($42.9M). Over the full record that is net buying of $20.3M.
How many insiders trade AUPH stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Aurinia Pharmaceuticals Inc.. The most recent filing was accepted on Sep 11, 2026.
Where does Trabud get AUPH insider trading data?
All AUPH insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.